Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEMASURE (HMSR) - Buyout in the works? -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (74)	6/10/1999 4:39:00 PM
From: RRICH4	Read Replies (1) \| Respond to of 88

HEMASURE INC. WINS APPEAL OF SUMMARY JUDGMENT AGAINST PALL Corporation HemaSure's Former LeukoNet Blood Filtration Product Found Not to Infringe Pall Patent MARLBOROUGH, Mass., June 9 /PRNewswire/ -- HemaSure Inc. (OTC Bulletin Board: HMSR), announced today that the U.S. Court of Appeals for the Federal Circuit determined that HemaSure's LeukoNet blood filtration product did not infringe claim 39 of Pall Corporation's ("Pall") U.S. Patent No. 5,451,321 (the "321 patent"). The June 8, 1999 decision of the Court of Appeals reverses an earlier district court decision and held that judgment of noninfringement be entered in favor of HemaSure. Stated Jack McGuire, President and CEO of HemaSure, "This is an extremely important win for HemaSure and we are very pleased that the court has determined that our LeukoNet product did not infringe the Pall patent. Although this decision relates to a product that we discontinued in 1998, it is testimony to the efforts we make to develop our own unique technology to meet our customers' needs." "We have consistently maintained our belief that our innovative designs do not infringe on Pall's or anyone else's patents. We are proud of our technological developments and have employed the same level of care and effort in the development of our recently introduced r\LS Red Blood Cell Filtration System," concluded McGuire. Background to the Decision Pall originally brought suit against HemaSure on February 2, 1996 and alleged that HemaSure's LeukoNet product infringed claims 39 and 45 of the '321 patent. In October 1997, the United States District Court for the Eastern District of New York entered judgment in favor of HemaSure on claim 45. Pall did not appeal that ruling. The District Court also entered judgment that HemaSure infringed claim 39, but that ruling has now been reversed by the Court of Appeal's June 8, 1999 decision. The Court of Appeal's decision in favor of HemaSure disposes of all of Pall's claims against HemaSure in the '321 patent infringement action. In the current quarter, HemaSure has completed a private placement financing with its distribution partner COBE BCT, Inc., a business unit of Gambro AB, and received U.S. FDA clearance to begin marketing its r\LS Red Blood Cell Filtration System in the U.S. HemaSure Inc. develops and delivers innovative filtration technologies designed to set standards of safety for processing blood components worldwide. Any statements contained herein that are not historical facts are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Potential factors could cause actual results to differ materially from those expressed or implied by such statements. These factors include, but are not limited to, those related to the outcome of other outstanding lawsuits with Pall Corporation. Information on the potential factors that could affect the Company's actual results of operations are included in its filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 1998. SOURCE HemaSure Inc. -0- 06/09/99 /CONTACT: James B. Murphy, Senior Vice President, Finance and Administration of HemaSure Inc., 508-485-6850/ (HMSR) CO: HemaSure Inc. ST: Massachusetts IN: MTC SU: -0- Jun/09/1999 13:58 EOS (PRN) Jun/09/99 13:58 ** -0-